KEGG   DRUG: Somatropin
Entry
D02691                      Drug                                   
Name
Somatropin (USP/INN);
Somatropin (genetical recombination) (JAN);
Human growth hormone (JAN);
Asellacrin (TN);
Humatrope (TN);
Nutropin (TN);
Omnitrope (TN)
Product
GENOTROPIN (Pfizer Laboratories Div Pfizer), HUMATROPE (Eli Lilly and Company), NORDITROPIN (Novo Nordisk), OMNITROPE (Sandoz), SAIZEN (EMD Serono), SEROSTIM (EMD Serono), SOMATROPIN (Genentech), ZOMACTON (Ferring Pharmaceuticals)
Formula
C990H1528N262O300S7
Exact mass
22111.0409
Mol weight
22124.7557
Sequence
FPTIPLSRLF DNAMLRAHRL HQLAFDTYQE FEEAYIPKEQ KYSFLQNPQT SLCFSESIPT
PSNREETQQK SNLELLRISL LLIQSWLEPV QFLRSVFANS LVYGASDSNV YDLLKDLEEG
IQTLMGRLED GSPRTGQIFK QTYSKFDTNS HNDDALLKNY GLLYCFRKDM DKVETFLRIV
QCRSVEGSCG F
(Disulfide bridge: 53-165, 182-189)
  Type
Peptide
Class
Hormonal agent
 DG03170  Growth hormone receptor agonist
Metabolizing enzyme inhibitor
 DG01933  CYP2C19 inhibitor
Remark
Therapeutic category: 2412
ATC code: H01AC01
Product: D02691<JP/US>
Efficacy
Growth hormone (GH) receptor agonist
  Disease
HIV patient [DS:H01563]
Growth hormone deficiency [DS:H00254]
Comment
human growth hormone derivative
Target
GHR [HSA:2690] [KO:K05080]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04080  Neuroactive ligand-receptor interaction
hsa04935  Growth hormone synthesis, secretion and action
  Network
nt06324  GHRH-GH-IGF signaling
Interaction
CYP inhibition: CYP2C19 [HSA:1557]
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
  H01 PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
   H01A ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES
    H01AC Somatropin and somatropin agonists
     H01AC01 Somatropin
      D02691  Somatropin (USP/INN) <JP/US>
USP drug classification [BR:br08302]
 Gastrointestinal Agents
  Gastrointestinal Agents, Other
   Somatropin
    D02691  Somatropin (USP/INN)
 Hormonal Agents, Stimulant/Replacement/Modifying (Pituitary)
  Somatropin
   D02691  Somatropin (USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 2  Agents affecting individual organs
  24  Hormones
   241  Pituitary hormone preparations
    2412  Anterior pituitary hormones
     D02691  Somatropin (USP/INN); Somatropin (genetical recombination) (JAN); Human growth hormone (JAN)
Drug groups [BR:br08330]
 Hormonal agent
  DG03170  Growth hormone receptor agonist
   D02691  Somatropin
 Metabolizing enzyme inhibitor
  DG01933  CYP2C19 inhibitor
   D02691  Somatropin
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   CSF and other factor receptors
    GHR
     D02691  Somatropin (USP/INN) <JP/US>
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D02691
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D02691
Other DBs
CAS: 12629-01-5
PubChem: 17396860
NIKKAJI: J246.949I
LinkDB

» Japanese version   » Back

KEGG   DRUG: Mecasermin
Entry
D03297                      Drug                                   
Name
Mecasermin (USAN/INN);
Mecasermin (genetical recombination) (JAN);
Increlex (TN);
Myotrophin (TN)
Product
INCRELEX (Ipsen Biopharmaceuticals)
Formula
C331H512N94O101S7
Exact mass
7643.5862
Mol weight
7648.6312
Sequence
GPETLCGAEL VDALQFVCGD RGFYFNKPTG YGSSSRRAPQ TGIVDECCFR SCDLRRLEMY
CAPLKPAKSA
(Disulfide bridge: 6-48, 18-61, 47-52)
  Type
Peptide
Remark
Therapeutic category: 2499
ATC code: H01AC03
Chemical structure group: DG01359
Product (DG01359): D03297<JP/US>
Efficacy
Antidiabetic, Insulin-like growth factor receptor agonist
  Disease
Primary IGF-1 deficiency [DS:H02040]
Comment
Recombinant Human Insulin-like growth factor I [HSA:3479] [KO:K05459]
Treatment of amyotrophic lateral sclerosis, Treatment of diabetes mellitus (types I and types II), Treatment of growth hormone insensitivity (GHIS)
Target
IGF1R (CD221) [HSA:3480] [KO:K05087]
GHR [HSA:2690] [KO:K05080]
  Pathway
hsa04151  PI3K-Akt signaling pathway
hsa04935  Growth hormone synthesis, secretion and action
  Network
nt06324  GHRH-GH-IGF signaling
nt06518  JAK-STAT signaling
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
  H01 PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
   H01A ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES
    H01AC Somatropin and somatropin agonists
     H01AC03 Mecasermin
      D03297  Mecasermin (USAN/INN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
 2  Agents affecting individual organs
  24  Hormones
   249  Miscellaneous
    2499  Others
     D03297  Mecasermin (USAN/INN); Mecasermin (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   INSR family
    IGF1R (CD221)
     D03297  Mecasermin (USAN/INN) <JP/US>
 Cytokines and receptors
  Cytokine receptors
   CSF and other factor receptors
    GHR
     D03297  Mecasermin (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D03297
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D03297
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D03297
Other DBs
CAS: 68562-41-4
PubChem: 17397448
NIKKAJI: J2.215.442G
LinkDB

» Japanese version   » Back

KEGG   DRUG: Pegvisomant
Entry
D05394                      Drug                                   
Name
Pegvisomant (USAN/INN);
Pegvisomant (genetical recombination) (JAN);
Somavert (TN)
Product
SOMAVERT (Pharmacia & Upjohn Company LLC)
Sequence
FPTIPLSRLF DNAMLRADRL NQLAFDTYQE FEEAYIPKEQ KYSFLQNPQT SLCFSESIPT
PSNREETQQK SNLELLRISL LLIQSWLEPV QFLRSVFANS LVYGASDSNV YDLLKDLEEK
IQTLMGRLED GSPRTGQIFK QTYSKFDTNS HNDDALLKNY GLLYCFNADM SRVSTFLRTV
QCRSVEGSCG F
  Type
Peptide
Remark
Therapeutic category: 2499
ATC code: H01AX01
Product: D05394<JP/US>
Efficacy
Growth hormone receptor antagonist
  Disease
Acromegaly [DS:H01483]
Comment
Treatment of acromegaly (competitive inhibition of peripheral growth hormone receptors to block IFG-I production)
Target
GHR [HSA:2690] [KO:K05080]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04080  Neuroactive ligand-receptor interaction
hsa04935  Growth hormone synthesis, secretion and action
  Network
nt06324  GHRH-GH-IGF signaling
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
  H01 PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
   H01A ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES
    H01AX Other anterior pituitary lobe hormones and analogues
     H01AX01 Pegvisomant
      D05394  Pegvisomant (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Hormonal Agents, Suppressant (Pituitary)
  Pegvisomant
   D05394  Pegvisomant (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 2  Agents affecting individual organs
  24  Hormones
   249  Miscellaneous
    2499  Others
     D05394  Pegvisomant (USAN/INN); Pegvisomant (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   CSF and other factor receptors
    GHR
     D05394  Pegvisomant (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D05394
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D05394
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D05394
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D05394
Other DBs
CAS: 218620-50-9
PubChem: 47207070
NIKKAJI: J2.535.243B
LinkDB

» Japanese version   » Back

KEGG   DRUG: Somatrogon
Entry
D10990                      Drug                                   
Name
Somatrogon (USAN/INN);
Somatrogon (genetical recombination) (JAN);
Somatrogon-ghla;
Ngenla (TN)
Product
NGENLA (Pfizer Laboratories Div Pfizer)
Remark
Therapeutic category: 2412
ATC code: H01AC08
Product: D10990<JP/US>
Efficacy
Replenisher (somatotoropin)
  Disease
Growth hormone deficiency [DS:H00254]
Target
GHR [HSA:2690] [KO:K05080]
  Pathway
hsa04080  Neuroactive ligand-receptor interaction
hsa04935  Growth hormone synthesis, secretion and action
  Network
nt06324  GHRH-GH-IGF signaling
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
  H01 PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
   H01A ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES
    H01AC Somatropin and somatropin agonists
     H01AC08 Somatrogon
      D10990  Somatrogon (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Hormonal Agents, Stimulant/Replacement/Modifying (Pituitary)
  Somatrogon
   D10990  Somatrogon (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 2  Agents affecting individual organs
  24  Hormones
   241  Pituitary hormone preparations
    2412  Anterior pituitary hormones
     D10990  Somatrogon (USAN/INN); Somatrogon (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   CSF and other factor receptors
    GHR
     D10990  Somatrogon (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10990
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10990
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10990
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10990
Other DBs
CAS: 1663481-09-1
PubChem: 342581831
LinkDB

» Japanese version   » Back

KEGG   DRUG: Somapacitan
Entry
D11194                      Drug                                   
Name
Somapacitan (USAN/INN);
Somapacitan (genetical recombination) (JAN);
Somapacitan-beco;
Sogroya (TN)
Product
SOGROYA (Novo Nordisk)
Formula
C1038H1609N273O319S9
Exact mass
23290.5561
Mol weight
23305.1048
Sequence
FPTIPLSRLF DNAMLRAHRL HQLAFDTYQE FEEAYIPKEQ KYSFLQNPQT SLCFSESIPT
PSNREETQQK SNLELLRISL LLIQSWLEPV QFLRSVFANS CVYGASDSNV YDLLKDLEEG
IQTLMGRLED GSPRTGQIFK QTYSKFDTNS HNDDALLKNY GLLYCFRKDM DKVETFLRIV
QCRSVEGSCG F
(Disulfide bridge: 53-165, 182-189)
  Type
Peptide
Class
Hormonal agent
 DG03170  Growth hormone receptor agonist
Remark
Therapeutic category: 2412
ATC code: H01AC07
Product: D11194<JP/US>
Efficacy
Growth hormone (GH) receptor agonist
  Disease
Growth hormone deficiency [DS:H00254]
Comment
Treatment of growth hormone dificiency
albumin-binding growth hormone
Target
GHR [HSA:2690] [KO:K05080]
  Pathway
hsa04080  Neuroactive ligand-receptor interaction
hsa04935  Growth hormone synthesis, secretion and action
  Network
nt06324  GHRH-GH-IGF signaling
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
  H01 PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
   H01A ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES
    H01AC Somatropin and somatropin agonists
     H01AC07 Somapacitan
      D11194  Somapacitan (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Hormonal Agents, Stimulant/Replacement/Modifying (Pituitary)
  Somapacitan
   D11194  Somapacitan (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 2  Agents affecting individual organs
  24  Hormones
   241  Pituitary hormone preparations
    2412  Anterior pituitary hormones
     D11194  Somapacitan (USAN/INN); Somapacitan (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Hormonal agent
  DG03170  Growth hormone receptor agonist
   D11194  Somapacitan
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   CSF and other factor receptors
    GHR
     D11194  Somapacitan (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11194
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11194
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D11194
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11194
Other DBs
CAS: 1338578-34-9
PubChem: 384585173
LinkDB

» Japanese version   » Back

KEGG   DRUG: Lonapegsomatropin
Entry
D11486                      Drug                                   
Name
Lonapegsomatropin (USAN/INN);
Lonapegsomatropin-tcgd;
Skytrofa (TN)
Product
SKYTROFA (Ascendis Pharma Endocrinology)
Sequence
FPTIPLSRLF DNAMLRAHRL HQLAFDTYQE FEEAYIPKEQ KYSFLQNPQT SLCFSESIPT
PSNREETQQK SNLELLRISL LLIQSWLEPV QFLRSVFANS LVYGASDSNV YDLLKDLEEG
IQTLMGRLED GSPRTGQIFK QTYSKFDTNS HNDDALLKNY GLLYCFRKDM DKVETFLRIV
QCRSVEGSCG F
(Disulfide bridge: 53-165, 182-189)
  Type
Peptide
Class
Hormonal agent
 DG03170  Growth hormone receptor agonist
Remark
ATC code: H01AC09
Product: D11486<US>
Efficacy
Growth hormone (GH) receptor agonist
  Disease
Growth hormone deficiency [DS:H00254]
Comment
Treatment of growth hormone deficiency
Target
GHR [HSA:2690] [KO:K05080]
  Pathway
hsa04080  Neuroactive ligand-receptor interaction
hsa04935  Growth hormone synthesis, secretion and action
  Network
nt06324  GHRH-GH-IGF signaling
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
  H01 PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
   H01A ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES
    H01AC Somatropin and somatropin agonists
     H01AC09 Lonapegsomatropin
      D11486  Lonapegsomatropin (USAN/INN) <US>
USP drug classification [BR:br08302]
 Hormonal Agents, Stimulant/Replacement/Modifying (Pituitary)
  Lonapegsomatropin
   D11486  Lonapegsomatropin (USAN/INN)
Drug groups [BR:br08330]
 Hormonal agent
  DG03170  Growth hormone receptor agonist
   D11486  Lonapegsomatropin
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   CSF and other factor receptors
    GHR
     D11486  Lonapegsomatropin (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11486
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11486
Other DBs
CAS: 1934255-39-6
PubChem: 384585462
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system